Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

14.19
-0.39 (-2.67%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :488,140
Date :07-30-2021

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Pharmaceuticals Appoints Chief Commercial Officer

July 29th, 2021|Comments Off on Oramed Pharmaceuticals Appoints Chief Commercial Officer

NEW YORK, July 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Michael Rabinowitz [...]

Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

July 21st, 2021|Comments Off on Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

- Oravax's virus-like particle (VLP) vaccine being tested against COVID-19 variants including Delta - Oravax signs licensing deal for VLP injectable vaccine technology with Premas Biotech for commercialization in India NEW YORK, July 21, 2021 [...]

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

June 22nd, 2021|Comments Off on Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

NEW YORK, June 22, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it is set to join [...]

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

June 8th, 2021|Comments Off on Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

First and Largest of two concurrent Phase 3 trials on track to complete randomization by Q4 2021 NEW YORK, June 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical [...]